{"transactions":[{"id":832421,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":56844,"kind":"person","name":"Bhat Laxminarayan","position":1,"cik":"0001818245","reported_name":"Bhat Laxminarayan","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-20T17:00:20.000Z","date":"2026-03-18","kind":"grant","planned":false,"acquired":true,"shares":40925,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This option award was made on the Grant Date in accordance with the terms of the Issuer's 2020 Plan. The option provides for vesting as follows: (i) 12,789 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 28,136 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option award was made on the Grant Date in accordance with the terms of the Issuer's 2020 Plan. The option provides for vesting as follows: (i) 12,789 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 28,136 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan."}],"balance_after":40925,"derivative":{"exercise_price":1.87,"expiration_date":"2036-03-17","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":40925},"source":{"system":"sec-edgar","filing":"0001437749-26-009258","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818245/000143774926009258/rdgdoc.xml","form_type":"4"}},{"id":832420,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":56844,"kind":"person","name":"Bhat Laxminarayan","position":1,"cik":"0001818245","reported_name":"Bhat Laxminarayan","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-20T17:00:20.000Z","date":"2026-03-18","kind":"grant","planned":false,"acquired":true,"shares":109150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This option award was made on March 18, 2026 (the \"Grant Date\") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The option provides for vesting as follows: (i) 34,110 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 75,040 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award was made on March 18, 2026 (the \"Grant Date\") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The option provides for vesting as follows: (i) 34,110 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 75,040 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan."}],"balance_after":109150,"derivative":{"exercise_price":1.87,"expiration_date":"2036-03-17","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":109150},"source":{"system":"sec-edgar","filing":"0001437749-26-009258","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818245/000143774926009258/rdgdoc.xml","form_type":"4"}},{"id":1263954,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":56844,"kind":"person","name":"Bhat Laxminarayan","position":1,"cik":"0001818245","reported_name":"Bhat Laxminarayan","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-18T16:30:30.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":181500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This option award was made on the Grant Date in accordance with the terms of the 2020 Plan. The option provides for vesting as follows:  (i) 75,625 of the shares subject to the option are immediately vested on the Grant Date, (ii) 83,195 shares subject to the option will vest in equal installments on the last day of each month from March 2025 to December 2026, and (iii) 22,680 shares subject to the option will vest in equal installments on the last day of each month from January 2027 to December 2027. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option award was made on the Grant Date in accordance with the terms of the 2020 Plan. The option provides for vesting as follows:  (i) 75,625 of the shares subject to the option are immediately vested on the Grant Date, (ii) 83,195 shares subject to the option will vest in equal installments on the last day of each month from March 2025 to December 2026, and (iii) 22,680 shares subject to the option will vest in equal installments on the last day of each month from January 2027 to December 2027. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan."}],"balance_after":181500,"derivative":{"exercise_price":1.8,"expiration_date":"2035-02-12","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":181500},"source":{"system":"sec-edgar","filing":"0001437749-25-004220","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818245/000143774925004220/rdgdoc.xml","form_type":"4"}},{"id":1263953,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":56844,"kind":"person","name":"Bhat Laxminarayan","position":1,"cik":"0001818245","reported_name":"Bhat Laxminarayan","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-18T16:30:30.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":519000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This option award was made on February 13, 2025 (the \"Grant Date\") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The option provides for vesting as follows:  (i) 216,125 of the shares subject to the option are immediately vested on the Grant Date, (ii) 237,882 shares subject to the option will vest in equal installments on the last day of each month from March 2025 to December 2026, and (iii) 64,993 shares subject to the option will vest in equal installments on the last day of each month from January 2027 to December 2027. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award was made on February 13, 2025 (the \"Grant Date\") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The option provides for vesting as follows:  (i) 216,125 of the shares subject to the option are immediately vested on the Grant Date, (ii) 237,882 shares subject to the option will vest in equal installments on the last day of each month from March 2025 to December 2026, and (iii) 64,993 shares subject to the option will vest in equal installments on the last day of each month from January 2027 to December 2027. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan."}],"balance_after":519000,"derivative":{"exercise_price":1.8,"expiration_date":"2035-02-12","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":519000},"source":{"system":"sec-edgar","filing":"0001437749-25-004220","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818245/000143774925004220/rdgdoc.xml","form_type":"4"}},{"id":1405287,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":56844,"kind":"person","name":"Bhat Laxminarayan","position":1,"cik":"0001818245","reported_name":"Bhat Laxminarayan","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-09-17T17:01:57.000Z","date":"2024-09-15","kind":"grant","planned":false,"acquired":true,"shares":77843,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents an option award granted to Ms. Seema Bhat, the Issuer's Vice President for Program & Portfolio Management and the spouse of the Reporting Person, by the Compensation Committee on September 15, 2024, in accordance with the terms of the 2020 Plan. On the Grant Date, the Compensation Committee determined the amount of incentive bonus earned by Ms. Bhat for 2023 and determined that the Issuer would pay the incentive bonus in the form of fully vested options in lieu of cash payment. The exercise price of the option award is based on the closing price of the Issuer's common stock on September 13, 2024, in accordance with the terms of the 2020 Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents an option award granted to Ms. Seema Bhat, the Issuer's Vice President for Program & Portfolio Management and the spouse of the Reporting Person, by the Compensation Committee on September 15, 2024, in accordance with the terms of the 2020 Plan. On the Grant Date, the Compensation Committee determined the amount of incentive bonus earned by Ms. Bhat for 2023 and determined that the Issuer would pay the incentive bonus in the form of fully vested options in lieu of cash payment. The exercise price of the option award is based on the closing price of the Issuer's common stock on September 13, 2024, in accordance with the terms of the 2020 Plan."}],"balance_after":77843,"derivative":{"exercise_price":1.2,"expiration_date":"2034-09-14","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":77843},"source":{"system":"sec-edgar","filing":"0001437749-24-029388","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818245/000143774924029388/rdgdoc.xml","form_type":"4"}},{"id":1405286,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":56844,"kind":"person","name":"Bhat Laxminarayan","position":1,"cik":"0001818245","reported_name":"Bhat Laxminarayan","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-09-17T17:01:57.000Z","date":"2024-09-15","kind":"grant","planned":false,"acquired":true,"shares":158451,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an option award granted to Dr. Laxminarayan Bhat, the Issuer's President and Chief Executive Officer (the \"Reporting Person\"), by the Issuer's compensation committee (the \"Compensation Committee\") on September 15, 2024 (the \"Grant Date\") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). On the Grant Date, the Compensation Committee determined the amount of incentive bonus earned by Dr. Bhat for 2023 and determined that the Issuer would pay the incentive bonus in the form of fully vested options in lieu of cash payment. The exercise price of the option award is based on the closing price of the Issuer's common stock on September 13, 2024, in accordance with the terms of the 2020 Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an option award granted to Dr. Laxminarayan Bhat, the Issuer's President and Chief Executive Officer (the \"Reporting Person\"), by the Issuer's compensation committee (the \"Compensation Committee\") on September 15, 2024 (the \"Grant Date\") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). On the Grant Date, the Compensation Committee determined the amount of incentive bonus earned by Dr. Bhat for 2023 and determined that the Issuer would pay the incentive bonus in the form of fully vested options in lieu of cash payment. The exercise price of the option award is based on the closing price of the Issuer's common stock on September 13, 2024, in accordance with the terms of the 2020 Plan."}],"balance_after":158451,"derivative":{"exercise_price":1.2,"expiration_date":"2034-09-14","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":158451},"source":{"system":"sec-edgar","filing":"0001437749-24-029388","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818245/000143774924029388/rdgdoc.xml","form_type":"4"}},{"id":1912428,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":56844,"kind":"person","name":"Bhat Laxminarayan","position":1,"cik":"0001818245","reported_name":"Bhat Laxminarayan","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-04-27T16:31:00.000Z","date":"2023-04-25","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents an option award granted to Ms. Seema Bhat, the Issuer's Vice President for Program & Portfolio Management and the spouse of the Reporting Person, by the Issuer's compensation committee on April 25, 2023 (the \"Grant Date\") in accordance with the terms of the 2020 Plan. The option vested as to fifty percent (50%) of the shares subject thereto on the Grant Date, and will vest as to an additional 1.389% of the shares subject thereto on the last day of each month thereafter. The exercise price is based on the closing price of the Issuer's common stock on the Grant Date in accordance with the terms of the 2020 Plan."}],"balance_after":150000,"derivative":{"exercise_price":6.74,"expiration_date":"2033-04-24","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001437749-23-011381","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818245/000143774923011381/rdgdoc.xml","form_type":"4"}},{"id":1912427,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":56844,"kind":"person","name":"Bhat Laxminarayan","position":1,"cik":"0001818245","reported_name":"Bhat Laxminarayan","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-04-27T16:31:00.000Z","date":"2023-04-25","kind":"grant","planned":false,"acquired":true,"shares":443000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an option award granted to Dr. Laxminarayan Bhat, the Issuer's President and Chief Executive Officer (the \"Reporting Person\"), by the Issuer's compensation committee on April 25, 2023 (the \"Grant Date\") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The option vested as to fifty percent (50%) of the shares subject thereto on the Grant Date, and will vest as to an additional 1.389% of the shares subject thereto on the last day of each month thereafter. The exercise price is based on the closing price of the Issuer's common stock on the Grant Date in accordance with the terms of the 2020 Plan."}],"balance_after":443000,"derivative":{"exercise_price":6.74,"expiration_date":"2033-04-24","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":443000},"source":{"system":"sec-edgar","filing":"0001437749-23-011381","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818245/000143774923011381/rdgdoc.xml","form_type":"4"}}]}